Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.
You may also be interested in...
Pharma Deals With The DOJ
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
Pfizer Protonix Settlement May Deter Price Bundling
$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.
FDA Generic Labeling Reg Could Fuel Suits Against Brands As Well
Proposed rule’s 30-day deadline for adoption of a generic’s approved label change could set standard for following brand’s revision; brands could be sued for picking one generic label change over another.